Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma (IFM2018-01)

July 29, 2020 updated by: University Hospital, Toulouse

Toward a Risk-adapted Strategy to Cure Myeloma : An Intensive Program With Lenalidomide, Ixazomib, and Dexamethasone Plus Daratumumab as Extended Induction and Consolidation Followed by Lenalidomide Maintenance in Newly Diagnosed Standard Risk Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant : a Phase II Study of the Intergroupe Francophone du Myélome (IFM)

The main objective of this study is to evaluate the minimal residual disease-negativity rate after administration of the combination of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab as induction and consolidation therapy in an intensive program in newly diagnosed standard risk multiple myeloma patients.

For the induction therapy, each patient received 6 cycles of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab, then peripheral blood stem cell harvest, intensification with autologous stem cell transplantation, consolidation therapy and maintenance.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This is a phase II, multicenter, non-randomized, open-label study to evaluate the safety and efficacy of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in patients with newly diagnosed multiple myeloma.

The patient population will consist of adult men and women ≤ 65 years, who have a confirmed diagnosis of standard risk multiple myeloma, who meet eligibility criteria.

Treatment periods will be defined as 21-day cycles for induction, and 28-day cycles for consolidation, and maintenance. Patients will be seen at regular treatment cycle intervals while they are participating in the study.

Patients will be assessed for disease response and progression according to the International Myeloma Working Group criteria at each cycle during induction and consolidation and every other cycle during maintenance.

Eastern Cooperative Oncology Group performance status, adverse events, laboratory values, and vital sign measurements will be collected and assessed to evaluate the safety of therapy throughout the study.

Toxicity will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events. Patients will attend an End of Treatment visit after receiving their last dose of study drug and will continue to be followed for other follow-up assessments specified in the Schedule of events.

All patients will be followed for survival after progression.

Study Type

Interventional

Enrollment (Anticipated)

45

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • France
      • Bordeaux, France
        • Not yet recruiting
        • CHU Bordeaux
        • Contact:
          • Cyrille HULIN
      • Caen, France
        • Not yet recruiting
        • CHU de Caen
        • Contact:
          • Margaret MACRO
      • Dijon, France
        • Not yet recruiting
        • CHU de Dijon
      • Grenoble, France
        • Not yet recruiting
        • CHU de Grenoble
        • Contact:
          • Clara MARIETTE
      • Lille, France
        • Not yet recruiting
        • CHRU de Lille
        • Contact:
          • Thierry FACON
      • Lyon, France
        • Not yet recruiting
        • Hospices Civils de Lyon
        • Contact:
          • Lionel KARLIN
      • Marseille, France
        • Not yet recruiting
        • Institut Paoli Calmettes
        • Contact:
          • Anne-Marie STOPPA
      • Nancy, France
        • Not yet recruiting
        • CHRU de Nancy
      • Nantes, France
        • Not yet recruiting
        • CHU de Nantes
        • Contact:
          • Philippe MOREAU
      • Rennes, France
        • Not yet recruiting
        • CHU de Rennes
        • Contact:
          • Martine ESCOFFRE
      • Toulouse, France, 31000
        • Recruiting
        • University Hosptial toulouse
        • Contact:
          • Michel Attal, MD PhD
      • Tours, France
        • Not yet recruiting
        • CHU de Tours
        • Contact:
          • Lotfi BENBOUBKER

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • De novo symptomatic myeloma on the International Myeloma Working Group Diagnostic Criteria for the Diagnosis of Multiple Myeloma
  • Measurable disease requiring systemic therapy defined by serum M-component ≥ 10g/l or urine M-component ≥ 200 mg/24h or involved free light level ≥ 100 mg/l
  • Eastern Cooperative Oncology Group performance status 0, 1 or 2
  • Eligible to high dose therapy

Exclusion Criteria:

  • Previously treated with any systemic therapy for multiple myeloma
  • Clinical signs of central nervous system involvement
  • Renal insufficiency defined as estimated Glomerular Filtration Rate lower or equal to 40 ml/min/1.73 m2
  • Hepatic impairment defined as aspartate transminase or alanine transaminase greater or equal to 3 x upper limit of normal, or Total bilirubin greater or equal to 3 x upper limit of normal
  • Platelet count < 75,000 per µL
  • Absolute neutrophil count ≤ 1,000 cells/mm3
  • Evidence of current uncontrolled cardiovascular conditions
  • Female patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening
  • Infection requiring systemic antibiotic therapy or other serious infection within 14 days before first dose of study drug
  • Grade 3 or higher peripheral neuropathy, or grade 2 with pain, on clinical examination during the screening period
  • Known or suspected chronic obstructive pulmonary disease with a Forced Expiratory Volume in 1 second < 50% of predicted normal
  • Systemic treatment with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of St. John's wort within 14 days before initiation of the study drug

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: four drugs combination
21-day cycles induction, then 28-day cycles consolidation and maintenance with Lenalidomide, Ixazomib, and Dexamethasone Plus Daratumumab
Drug: Ixazomib
21-day cycles induction and 28-day cycles consolidation
Drug: Lenalidomide
21-day cycles induction and 28-day cycles consolidation and 28-day cycles maintenance therapy
Drug: Dexamethasone
21-day cycles induction and 28-day cycles consolidation
Drug: Daratumumab
21-day cycles induction and 28-day cycles consolidation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
minimal residual disease-negativity rate
Time Frame: 22 months
after completion of the consolidation therapy and before maintenance
22 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall survival
Time Frame: 54 months
54 months
Adverse events
Time Frame: up to 54 Months
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
up to 54 Months
Response rates
Time Frame: 3 months, 5 months, 7 months, 13 months, 25 months
Response rates according to the IMWG criteria after induction, high dose Melphalan, consolidation and maintenance therapy
3 months, 5 months, 7 months, 13 months, 25 months
Progression free survival
Time Frame: 54 months
54 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Toulouse

Investigators

  • Study Director: Michel ATTAL, MD, University Hospital, Toulouse

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

December 31, 2018

Primary Completion (ANTICIPATED)

March 1, 2024

Study Completion (ANTICIPATED)

December 1, 2024

Study Registration Dates

First Submitted

September 11, 2018

First Submitted That Met QC Criteria

September 11, 2018

First Posted (ACTUAL)

September 13, 2018

Study Record Updates

Last Update Posted (ACTUAL)

July 30, 2020

Last Update Submitted That Met QC Criteria

July 29, 2020

Last Verified

July 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RC31/18/0212

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Myeloma

Clinical Trials on Ixazomib

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe